RATIONALE: The rapid membrane actions of neuroactive steroids, particularly via an enhancement of γ-aminobutyric acidA receptors (GABAARs), participate in the regulation of central nervous system excitability. Prior evidence suggests an inverse relationship between endogenous GABAergic neuroactive steroid levels and behavioral changes in excitability during ethanol withdrawal. OBJECTIVES: Previously, we found that ethanol withdrawal significantly decreased plasma allopregnanolone (ALLO) levels, a potent GABAergic neuroactive steroid, and decreased GABAAR sensitivity to ALLO in Withdrawal Seizure-Prone (WSP) but not in Withdrawal Seizure-Resistant (WSR) mice. However, the effect of ethanol withdrawal on levels of other endogenous GABAAR-active steroids is not known. METHODS: After validation of a gas chromatography-mass spectrometry method for the simultaneous quantification of ten neuroactive steroids, we analyzed plasma from control male WSP-1 and WSR-1 mice and during ethanol withdrawal. RESULTS: We quantified levels of nine neuroactive steroids in WSP-1 and WSR-1 plasma; levels of pregnanolone were not detectable. Basal levels of five neuroactive steroids were higher in WSR-1 versus WSP-1 mice. Ethanol withdrawal significantly suppressed five neuroactive steroids in WSP-1 and WSR-1 mice, including ALLO. CONCLUSIONS: Due to lower basal levels of some GABAAR-active steroids in WSP-1 mice, a withdrawal-induced decrease in WSP-1 mice may have a greater physiological consequence than a similar decrease in WSR-1 mice. Because WSP-1 mice also exhibit a reduction in GABAAR sensitivity to neuroactive steroids during withdrawal, it is possible that the combined decrease in neuroactive steroids and GABAAR sensitivity during ethanol withdrawal in WSP-1 mice represents a neurochemical substrate for severe ethanol withdrawal.
RATIONALE: The rapid membrane actions of neuroactive steroids, particularly via an enhancement of γ-aminobutyric acidA receptors (GABAARs), participate in the regulation of central nervous system excitability. Prior evidence suggests an inverse relationship between endogenous GABAergic neuroactive steroid levels and behavioral changes in excitability during ethanol withdrawal. OBJECTIVES: Previously, we found that ethanol withdrawal significantly decreased plasma allopregnanolone (ALLO) levels, a potent GABAergic neuroactive steroid, and decreased GABAAR sensitivity to ALLO in Withdrawal Seizure-Prone (WSP) but not in Withdrawal Seizure-Resistant (WSR) mice. However, the effect of ethanol withdrawal on levels of other endogenous GABAAR-active steroids is not known. METHODS: After validation of a gas chromatography-mass spectrometry method for the simultaneous quantification of ten neuroactive steroids, we analyzed plasma from control male WSP-1 and WSR-1 mice and during ethanol withdrawal. RESULTS: We quantified levels of nine neuroactive steroids in WSP-1 and WSR-1 plasma; levels of pregnanolone were not detectable. Basal levels of five neuroactive steroids were higher in WSR-1 versus WSP-1 mice. Ethanol withdrawal significantly suppressed five neuroactive steroids in WSP-1 and WSR-1 mice, including ALLO. CONCLUSIONS: Due to lower basal levels of some GABAAR-active steroids in WSP-1 mice, a withdrawal-induced decrease in WSP-1 mice may have a greater physiological consequence than a similar decrease in WSR-1 mice. Because WSP-1 mice also exhibit a reduction in GABAAR sensitivity to neuroactive steroids during withdrawal, it is possible that the combined decrease in neuroactive steroids and GABAAR sensitivity during ethanol withdrawal in WSP-1 mice represents a neurochemical substrate for severe ethanol withdrawal.
Authors: Tillmann H C Krüger; Paul Brink; Marion U Goebel; Boris Schiffer; Manfred Schedlowski; Uwe Hartmann; Udo Schneider Journal: Addict Biol Date: 2006-06 Impact factor: 4.280
Authors: Martin Hill; Petr Popov; Helena Havlíková; Lyudmila Kancheva; Jana Vrbíková; Radmila Kancheva; Vladimír Pouzar; Ivan Cerný; Luboslav Stárka Journal: Steroids Date: 2005-03-28 Impact factor: 2.668
Authors: E Romeo; A Brancati; A De Lorenzo; P Fucci; C Furnari; E Pompili; G F Sasso; G Spalletta; A Troisi; A Pasini Journal: Clin Neuropharmacol Date: 1996-08 Impact factor: 1.592
Authors: Michelle A Nipper; Jeremiah P Jensen; Melinda L Helms; Matthew M Ford; John C Crabbe; David J Rossi; Deborah A Finn Journal: Neuroscience Date: 2018-12-02 Impact factor: 3.590
Authors: Jeremiah P Jensen; Michelle A Nipper; Melinda L Helms; Matthew M Ford; John C Crabbe; David J Rossi; Deborah A Finn Journal: Psychopharmacology (Berl) Date: 2017-06-29 Impact factor: 4.530
Authors: Leslie L Devaud; Mehrdad Alavi; Jeremiah P Jensen; Melinda L Helms; Michelle A Nipper; Deborah A Finn Journal: Alcohol Date: 2018-12-06 Impact factor: 2.405
Authors: Michelle A Tanchuck-Nipper; Matthew M Ford; Anna Hertzberg; Amy Beadles-Bohling; Debra K Cozzoli; Deborah A Finn Journal: Behav Genet Date: 2014-10-31 Impact factor: 2.805
Authors: Brandy L Dozier; Cara A Stull; Erich J Baker; Matthew M Ford; Jeremiah P Jensen; Deborah A Finn; Kathleen A Grant Journal: Psychopharmacology (Berl) Date: 2019-01-15 Impact factor: 4.530